TORONTO, Dec. 18, 2013 /CNW/ - Bayer Inc. is pleased to announce that
Bayer HealthCare has joined the Structural Genomics Consortium (SGC), a
not-for-profit, public-private partnership with active research
facilities at the Universities of Toronto and Oxford, UK. Bayer will
support funding the consortium to accelerate precompetitive drug
research in the areas of protein sciences and epigenetics. Furthermore,
Bayer will provide a subset of its compound library for screening to
the SGC and will also conduct the chemical work to identify probes. The
joint research efforts within the consortium may open up new
possibilities for the development of novel therapies - particularly in
"We are excited to join the SGC which has an impressive track record in
providing protein X-ray structures and chemical probes for epigenetics
research," said Prof. Hanno Wild, Senior Vice President and Head of
Candidate Generation & Exploration at Bayer HealthCare Global Drug
Discovery. "This unique public-private partnership combines the
strengths of first class academic and industrial partners in a large
global scientific network. While advancing the field by discovering new
probes, we hope to gain a better understanding of disease processes and
find new starting points for drug discovery programs to speed up the
development of new medicines in areas with a high unmet medical need."
The SGC and Bayer HealthCare will collaborate on different research
projects in Toronto and Oxford with the goal to identify small
molecules that can interfere with the activity of proteins involved in
epigenetic control to unravel disease mechanisms. Chemical probes and
protein X-ray structures discovered under the collaboration will be put
in the public domain without restriction on use to provide tools
advancing research in epigenetics.
Epigenetics, in biology, refers to the study of heritable and acquired
changes in gene function that occur without a change in the underlying
DNA sequence. With new chemical probes to interrogate epigenetic
processes and X-ray structures of protein targets that increase the
understanding of binding events and allow for tailoring probes, the
scientific knowledge in this area may be significantly advanced. This
is hoped to pave the way for new drug discovery programs on previously
About the Structural Genomics Consortium (SGC)
With active research facilities at the Universities of Toronto and
Oxford, the not-for-profit organization supports the discovery of new
medicines by carrying open access research in structural and chemical
biology. More than 200 researchers in academia and in nine
pharmaceutical companies collaborate within SGC to accomplish these
goals. The SGC is also funded by the Canadian Foundation for
Innovation, Genome Canada, the Ontario Ministry of Economic Development
and Innovation, the Wellcome Trust and nine pharmaceutical companies.
More information is available at www.thesgc.org.
About Bayer in Canada
Bayer Inc. is a Canadian subsidiary of Bayer AG and the corporate
headquarters for its Canadian operations. Celebrating its 150th anniversary, Bayer AG is an international research-based group with
core businesses in healthcare, crop science and innovative materials
committed to creating a better life for all through science.
In Canada, Bayer operates its healthcare business - Pharmaceuticals,
Consumer Care, Diabetes Care, Animal Health and Radiology &
Interventional - from its headquarters in Toronto, ON and Bayer
CropScience Inc. operates out of its head office in Calgary, AB. With
more than 1,300 employees across the country, in 2012, Bayer had sales
of $1.6 billion and invested $55.9 million in research and development
in Canada. Globally, Bayer AG had sales of €39.8 billion and invested
€3 billion in research and development.
For more information about Bayer, please visit www.bayer.ca.
This release may contain forward-looking statements based on current
assumptions and forecasts made by Bayer Group or subgroup management.
Various known and unknown risks, uncertainties and other factors could
lead to material differences between the actual future results,
financial situation, development or performance of the company and the
estimates given here. These factors include those discussed in Bayer's
public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these
forward-looking statements or to conform them to future events or developments.
SOURCE: Bayer Inc.
For further information:
Marija Mandic, 416-240-5376
Diana Scholz, +49 30 468 193183